Microdosing and standard‐dosing take‐home buprenorphine from the emergency department: A feasibility study
J. Moe, K. Badke, Megan Pratt, Raymond Y. Cho, P. Azar, Heather Flemming, K. Sutherland, B. Harvey, Lara Gurney, Julie Lockington, Penny Brasher, Sam Gill, Emma Garrod, Misty Bath, A. Kestler
Journal of the American College of Emergency Physicians Open October 20, 2020 DOI: 10.1002/emp2.12289 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Feasibility study Peer reviewed |
|---|---|
| Intervention | Buprenorphine/naloxone |
| Topics | Microdosing |
| Key points | The authors propose that emergency department-initiated buprenorphine/naloxone, including a microdosing option that avoids withdrawal, may be a feasible approach to preventing overdose, and they set out to test the feasibility of delivering standard-dosing and microdosing take-home packages and of randomizing patients between them. No findings are reported in the available text. |
Abstract
Emergency department (ED)–initiated buprenorphine may prevent overdose. Microdosing is a novel approach that does not require withdrawal, which can be a barrier to standard inductions. We aimed to evaluate the feasibility of an ED‐initiated buprenorphine/naloxone program providing standard‐dosing and microdosing take‐home packages and of randomizing patients to either intervention.
Citations in the library
Cited by 2
- Buprenorphine Microdosing for the Pain and Palliative Care Clinician Journal of Palliative Medicine December 20, 2021
- Using Microdosing to Induct Patients Into a Long-Acting Injectable Buprenorphine Depot Medication in Low Threshold Community Settings: A Case Study Frontiers in Pharmacology March 23, 2021